GW Pharmaceuticals PLC- (GWPH) Lowered to Hold at BidaskClub

BidaskClub downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a report released on Tuesday morning.

Several other research firms have also weighed in on GWPH. Bank of America raised their price objective on shares of GW Pharmaceuticals PLC- from $170.00 to $200.00 and gave the stock a buy rating in a report on Tuesday, June 26th. Stifel Nicolaus started coverage on shares of GW Pharmaceuticals PLC- in a report on Tuesday, August 14th. They set a buy rating and a $181.00 price objective for the company. Morgan Stanley raised their price objective on shares of GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the stock an overweight rating in a report on Friday, September 28th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Friday, August 10th. Finally, Cantor Fitzgerald set a $235.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a buy rating in a report on Thursday, July 12th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $185.00.

NASDAQ GWPH opened at $143.32 on Tuesday. The company has a market cap of $4.80 billion, a PE ratio of -20.62 and a beta of 2.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21. GW Pharmaceuticals PLC- has a 1-year low of $101.07 and a 1-year high of $179.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.40) by $1.14. The company had revenue of $3.46 million during the quarter, compared to analyst estimates of $2.00 million. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. Equities analysts predict that GW Pharmaceuticals PLC- will post -9.11 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GWPH. Wells Fargo & Company MN grew its stake in shares of GW Pharmaceuticals PLC- by 20.6% during the first quarter. Wells Fargo & Company MN now owns 29,172 shares of the biopharmaceutical company’s stock valued at $3,288,000 after purchasing an additional 4,987 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of GW Pharmaceuticals PLC- by 4,345.8% during the first quarter. JPMorgan Chase & Co. now owns 20,984 shares of the biopharmaceutical company’s stock valued at $2,364,000 after purchasing an additional 20,512 shares during the last quarter. Sei Investments Co. grew its stake in shares of GW Pharmaceuticals PLC- by 3,653.6% during the first quarter. Sei Investments Co. now owns 2,102 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 2,046 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of GW Pharmaceuticals PLC- by 48.2% during the first quarter. Commonwealth Equity Services LLC now owns 10,383 shares of the biopharmaceutical company’s stock valued at $1,169,000 after purchasing an additional 3,376 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of GW Pharmaceuticals PLC- by 74.2% during the first quarter. UBS Group AG now owns 82,911 shares of the biopharmaceutical company’s stock valued at $9,341,000 after purchasing an additional 35,318 shares during the last quarter. 75.44% of the stock is currently owned by institutional investors and hedge funds.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply